scholarly journals Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus

2019 ◽  
Vol 4 (2) ◽  
pp. 277-286 ◽  
Author(s):  
Margarita Capel ◽  
Andreea Ciudin ◽  
María Mareque ◽  
Raquel María Rodríguez-Rincón ◽  
Susana Simón ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Receptor Agonists ◽  
Effectiveness Analysis

Intensive versus conventional treatment on patients with type-2 diabetes mellitus. A cost/effectiveness analysis

2015 ◽  
Vol 241 (1) ◽  
pp. e215
Author(s):  
M. Hernandez-Sanchez ◽  
C. Fernandez-Fernandez ◽  
A. Rodriguez-Guerrero ◽  
L. Martín-Fernandez ◽  
D. Barrio-Carreras ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Conventional Treatment ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis

scholarly journals Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus

2011 ◽  
Vol 14 (3) ◽  
pp. 111-112
Author(s):  
Alla Vsevolodovna Rudakova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Modified Release ◽  
2Nd Generation ◽  
Effectiveness Analysis ◽  
Sulfonylurea Drugs

In Russia, sulfonylurea drugs are extensively prescribed to patients with type 2 diabetes mellitus. This work was designed to study pharmacoeconomicaspects of application of 2nd generation sulfonylureas based on the results of the GUIDE study comparing effects of therapy with gliclazide modifiedrelease (diabeton MV) and glimepiride (amaryl). The two drugs are known to be equally effective, but gliclazide creates a much smaller risk ofhypoglycemia than glymepiride. Cost-effectiveness analysis showed that the use of gliclazide cuts the costs of therapy by 40%. It is concluded that thechoice of gliclazide modified release is economically more feasible than glimepiride.

scholarly journals COST-EFFECTIVENESS ANALYSIS OF INSULIN, SULFONYLUREA, AND SULFONYLUREA– METFORMIN IN TYPE 2 DIABETES MELLITUS

2017 ◽  
Vol 10 (17) ◽  
pp. 50 ◽  
Author(s):  
Endang Laelasari ◽  
Rani Sauriasari ◽  
Agusdini Banun
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Combination Group ◽  
Insulin Group ◽  
Effectiveness Analysis ◽  
Metformin Group

Objective: This study aims to compare the cost-effectiveness of insulin therapy, sulfonylureas, and combination of sulfonylureas-metformin in patients with type 2 diabetes mellitus in Sitanala Hospital, Tangerang.Methods: This study employed a cross-sectional to examine the effectiveness and cost of different treatments for Type 2 diabetes mellitus (T2DM) among outpatients at Dr. Sitanala Leprosy Hospital in Tangerang, using cost-effectiveness analysis. Participants had consumed the same drug over the past 4 months and were divided into three groups, as follows: An insulin group (n=29), sulfonylurea group (n=29), and sulfonylurea–metformin combination group (n=39). The effectiveness of treatment was evaluated by considering Hemoglobin A1c (HbA1c) values. The measured cost was direct medical cost.Results: The results showed that there were more female patients (65.96%) than male patients with T2DM, and their average age was 50-59 years. The highest effectiveness was shown in combination in the sulfonylurea–metformin group, with an HbA1c level of 7.48±1.89, although the difference was not statistically significant. The direct medical cost of sulfonylurea monotherapy was significantly lower than that of the other therapies. The average cost-to-effectiveness ratio in the insulin group was Rp. 40,866 that in the sulfonylurea group was Rp. 1,369 and that in the combination of sulfonylurea–metformin group was Rp. 2,621 per percentage of effectivity. The incremental cost-to-effectiveness ratio for the sulfonylurea–metformin to sulfonylurea monotherapy treatment was Rp. 16,194 per percentage effectivity.Conclusion: Based on the analysis performed, sulfonylurea–metformin combination therapy was more cost-effective than either sulfonylurea or insulin monotherapy.

Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis

2004 ◽  
Vol 140 (9) ◽  
pp. 689 ◽  
Author(s):  
Thomas J. Hoerger ◽  
Russell Harris ◽  
Katherine A. Hicks ◽  
Katrina Donahue ◽  
Stephen Sorensen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis
Sign in / Sign up

Export Citation Format

Share Document